Jaystine-M Tablet contains a combination of Bilastine 20 mg and Montelukast 10 mg, formulated for the management of allergic conditions. Bilastine is a second-generation antihistamine that selectively antagonizes peripheral H1 receptors, providing effective relief from symptoms such as rhinorrhea, sneezing, nasal congestion, and urticaria without causing significant sedation. Montelukast is a leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor, thereby reducing inflammation, bronchoconstriction, and mucus production associated with allergic rhinitis and asthma. The synergistic action of these two agents makes Jaystine-M effective in treating seasonal and perennial allergic rhinitis, chronic urticaria, and as an adjunct in asthma management. The tablet is generally well tolerated, with a low incidence of adverse effects such as headache, gastrointestinal discomfort, and fatigue. It is contraindicated in patients with known hypersensitivity to either component. Jaystine-M should be administered once daily, preferably in the evening, and dosage adjustments may be necessary in patients with hepatic impairment. Careful consideration is advised when prescribing to pregnant or lactating women. This combination therapy offers a convenient and comprehensive approach to controlling allergic symptoms and improving patient quality of life.